Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT05669599

Public ClinicalTrials.gov record NCT05669599. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).

Study identification

NCT ID
NCT05669599
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
592 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 17, 2023
Primary completion
Oct 7, 2024
Completion
Dec 15, 2025
Last update posted
Jan 19, 2026

2023 – 2025

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
23
Facility City State ZIP Site status
Alliance for Multispecialty Research Mobile Mobile Alabama 36608
Foothills Research Center Phoenix Arizona 85044
HonorHealth Scottsdale Arizona 85258
Ark Clinical Research- Long Beach Long Beach California 90815
Ark Clinical Research- Tustin Tustin California 92780
Orange County Research Center Tustin California 92780
Diablo Clinical Research Walnut Creek California 94598
Alliance for Multispecialty Research Miami Coral Gables Florida 33134
Progressive Medical Research Port Orange Florida 32127
East-West Medical Research Honolulu Hawaii 96814
University of Chicago Chicago Illinois 60637
Great Lakes Clinical Trials Chicago Illinois 60640
Alliance for Multispecialty Research Newton Newton Kansas 67114
Louisville Metabolic and Atherosclerosis Research Center Louisville Kentucky 40213
Tandem Clinical Research - Marrero Marrero Louisiana 70072
StudyMetrix Research City of Saint Peters Missouri 63303
Alliance for Multispecialty Research Kansas City Kansas City Missouri 64114
State University of New York Upstate Medical University Syracuse New York 13210
Lucas Research Morehead City North Carolina 28557
Research Innovations LLC dba Internal Medicine Care Inc Beavercreek Ohio 45431
The Christ Hospital Cincinnati Ohio 45219
Alliance for Multispecialty Research Norman Norman Oklahoma 73069
Medical Care LLC Elizabethton Tennessee 37643
PanAmerican Clinical Research LLC Brownsville Texas 78520
Headlands Research Brownsville Brownsville Texas 78526
Clinical Trials of Texas San Antonio Texas 78229
Diabetes and Glandular Disease Clinic San Antonio Texas 78229
Pinnacle Clinical Research San Antonio Texas 78229
Texas Diabetes Institute San Antonio Texas 78284

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05669599, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05669599 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →